Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study ( Angeles California; founder and direc...)

HOME >> MEDICINE >> TECHNOLOGY

Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study

Angeles, California; founder and director-emeritus of The New England Center for Headache; and clinical investigator for the Phase II study.

Merck continues to anticipate filing a New Drug Application (NDA) for MK-0974 with the U.S. Food and Drug Administration in 2009.

About migraines

Migraine headaches impact approximately 28 million Americans, primarily women. Unlike a bad headache, migraines are characterized by attacks of intense, usually one-sided, throbbing head pain that can last from four to 72 hours. The pain associated with migraine is frequently accompanied by other associated symptoms, including nausea, vomiting and increased sensitivity to light and/or sound.

About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com.

Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new i
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents

Post Your Comments:

(Date:11/9/2009).... 9 /PRNewswire/ -- On Sept. 11, 2001, thousands... workers came together to save as many lives as po... McCauley was one of those 9/11 first responders. ...y in his late 30s, McCauley was diagnosed with can...e chemotherapy treatments, leaving him confined to...

(Date:11/9/2009)...RNewswire/ -- Women,s sexual health company, TivaM...eve as it prepares for a 2010 launch of its Viveve...Viveve is a name that we believe captures the esse..." said Kerry Pope, Viveve,s president and chief ex...lping women restore their sense of fulfillment and...

(Date:11/9/2009)...swire-FirstCall/ -- Boston Scientific Corporation ...GNIS® cardiac resynchronization therapy defib...dioverter defibrillator (ICD) in Japan. These dev...lth, Labor and Welfare (MHLW) in August and receiv...d TELIGEN are the result of a multi-year research ...

Breaking Medicine Technology:The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 2 The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair 3 Women's Sexual Health Company Changes Name in Preparation for Market Entry 2 Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 2 Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 3 Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan 4 Greater Language Skills in 20s May Guard Against Alzheimers 51128 1 Greater Language Skills in 20s May Guard Against Alzheimers 51128 2 Greater Language Skills in 20s May Guard Against Alzheimers 51128 3 Inflammation may trigger Alzheimers disease Saint Louis University findings suggest 51126 1 Inflammation may trigger Alzheimers disease Saint Louis University findings suggest 51126 2 Mothers of children with autism have higher parental stress psychological distress 51125 1 Mothers of children with autism have higher parental stress psychological distress 51125 2 Mothers of children with autism have higher parental stress psychological distress 51125 3

[0] The SCOOTER Store Surprises 9/11 First Responder & Merrick Firefighter With Power Chair [0] Women's Sexual Health Company Changes Name in Preparation for Market Entry [0] Boston Scientific's Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan

...NNEAPOLIS, Jan. 13 /PRNewswire-FirstCall/ - - U...from a clinical study of Macroplastique for the tr... available in the January 2009 Journal of Urology...d trial comparing the safety and efficacy of Macro...trol group. In the Macroplastique group, the dry/c...

...N MATEO, Calif., Jan. 12 NeurogesX, Inc. (Nas... on developing and commercializing novel pain mana...of Phase 3 data of its lead product candidate, Qut... neuralgia (PHN) in the December 2008 print editio...vailable through Lancet Online at http://www.thel...

Other Medicine Technology:Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence 2 Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence 3 NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology 2 NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology 3 NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology 4

Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology

(Date:11/9/2009)... SHENZHEN, China, Nov. 9 /PRNewswire-Asia-FirstC...E: MR ), a leading developer, manufacturer and,ma...ay its selected unaudited,financial results for th...,2009. , , Highlights for Operations as of Se...enues were $151.1 million, an increase of, 3...

(Date:11/9/2009)...ACRAMENTO, Calif., Nov. 9 Sutter H...ls and other health care service providers, is don...ornia. A variety of local food banks will share th...-needed meals on the tables of thousands of famili...as a long history of partnering with and supportin...

(Date:11/9/2009)...ASHINGTON, Nov. 9 The Churchill ... Award For Leadership to J.W. "Bill" Marriott for ...ough progressive free market practices and fosteri.... Mr. Marriott will receive his award at a ceremon...gton D.C. Four Seasons Hotel. ,, "This is a te...

(Date:11/9/2009)...OS ANGELES, Nov. 9 Tracy Anderson,... and Kate Hudson, will be hosting two events at he... Finally sharing her long awaited Nutritional Mea...cing her TA Baby Food Cleanse and Lifestyle Menu. ...orporates her entire method of cardio and muscle s...

(Date:11/9/2009)...may be left atrial enlargement, study finds , ... is a major risk factor for left atrial enlargemen..., stroke and death, a new study shows. , Atrial...a (an irregular heart rhythm or heartbeat). , ...aged 25 to 74, in Germany who were followed for 10...

[0] Mindray Announces Third Quarter 2009 Financial Results [0] Sutter Health Donates $255,000 to Help the Hungry This Holiday Season [0] J.W. 'Bill' Marriott to Receive Churchill Centre Award For Leadership [0] Celebrity Trainer Tracy Anderson Sharing Her Fitness and Diet Secrets This Week [0] Obesity Seems to Alter Heart Structure

... , , "Go fast, deliver something provocative." ,...te with them." , "Revolutionary technological chan...aster you." , , ALEXANDRIA, Va., March 13 As the...arge to control costs, improve quality, and expand...

... Medical Center has received a $125 million gift f...cialty and cancer hospital complex at the UCSF Mis... is the largest support to date for the $600 milli...rom other philanthropists, was made by Charles F. ...

... Pa., March 13 Kensey Nash Corporation (Nasdaq: ...teenth Annual New York Emerging Growth Institution...ity on Tuesday, March 24, 2009. , , Joseph W. Kau...ilable on the company,s website ( www.kenseynash.c...

... , , Minimally-invasive oncologic surgery proced...prudent when recommending the option to their pati...mprehensive Cancer Center. Dr. D,Amico detailed t...ual Conference. , , HOLLYWOOD, Fla., March 13 C...

...suggests children with language disorders may bene...13 (HealthDay News) -- Musical training enhances t...r sounds, a finding that suggests that musical tra...l that translates across all arenas, whether in th...

...ta HPV HR: First FDA approved high-risk HPV test i...genotyping test approved by the FDA , , BEDFORD, ...mpany) (Nasdaq: HOLX ), a leading women,s health...pany,s premarket approval (PMA) applications for b...

Other Medicine News:Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 2 Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 3 Health News:APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change 4 Health News:UCSF Medical Center receives $125 million gift to build new hospital 2 Health News:UCSF Medical Center receives $125 million gift to build new hospital 3 Health News:UCSF Medical Center receives $125 million gift to build new hospital 4 Health News:Is Smaller Better? Minimally Invasive Oncologic Surgery Options Discussed at NCCN Conference 2 Health News:Is Smaller Better? Minimally Invasive Oncologic Surgery Options Discussed at NCCN Conference 3 Health News:Is Smaller Better? Minimally Invasive Oncologic Surgery Options Discussed at NCCN Conference 4 Health News:Musicians' Brains Tuned to Emotions in Sound 2 Health News:FDA Approves Two Hologic HPV Tests 2 Health News:FDA Approves Two Hologic HPV Tests 3 Health News:FDA Approves Two Hologic HPV Tests 4

APTA's Multidisciplinary Summit Establishes Opportunities for Physical Therapists to Drive Health Care Change UCSF Medical Center receives $125 million gift to build new hospital Kensey Nash to Participate in the Sidoti Thirteenth Annual New York Emerging Growth Institutional Investor Forum Conference Is Smaller Better? Minimally Invasive Oncologic Surgery Options Discussed at NCCN Conference Musicians' Brains Tuned to Emotions in Sound FDA Approves Two Hologic HPV Tests

... ARUP Laboratories is a national reference laborat...y research and development. ARUP offers an extensi...tests in clinical and anatomic pathology. Owned by...s include more than half of the nation's universit...

Medicine Products:

D-xylose (Adult-5 g dose)D-lysergic Acid Diethylamide, Urine D-lysergic Acid Diethylamide D, 25-Hydroxy, Vitamin

( Angeles California; founder and direc...)Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study,Health